<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p77" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_77{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_77{left:341px;bottom:30px;}
#t3_77{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_77{left:377px;bottom:30px;}
#t5_77{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_77{left:540px;bottom:30px;}
#t7_77{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_77{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_77{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_77{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_77{left:285px;bottom:827px;letter-spacing:-0.25px;}
#tc_77{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_77{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_77{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_77{left:1118px;bottom:47px;letter-spacing:0.34px;}
#tg_77{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_77{left:36px;bottom:344px;}
#ti_77{left:46px;bottom:338px;letter-spacing:0.13px;}
#tj_77{left:36px;bottom:329px;}
#tk_77{left:46px;bottom:323px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tl_77{left:377px;bottom:323px;letter-spacing:0.12px;}
#tm_77{left:407px;bottom:323px;letter-spacing:0.13px;}
#tn_77{left:481px;bottom:323px;}
#to_77{left:36px;bottom:314px;}
#tp_77{left:46px;bottom:308px;letter-spacing:0.1px;word-spacing:-0.02px;}
#tq_77{left:45px;bottom:293px;letter-spacing:0.13px;}
#tr_77{left:36px;bottom:283px;}
#ts_77{left:46px;bottom:277px;letter-spacing:0.12px;word-spacing:0.01px;}
#tt_77{left:36px;bottom:268px;}
#tu_77{left:46px;bottom:262px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tv_77{left:556px;bottom:262px;}
#tw_77{left:36px;bottom:253px;}
#tx_77{left:46px;bottom:247px;letter-spacing:0.12px;}
#ty_77{left:45px;bottom:232px;letter-spacing:0.13px;}
#tz_77{left:451px;bottom:239px;}
#t10_77{left:456px;bottom:232px;letter-spacing:0.12px;word-spacing:0.01px;}
#t11_77{left:45px;bottom:216px;letter-spacing:0.12px;word-spacing:0.01px;}
#t12_77{left:45px;bottom:201px;letter-spacing:0.11px;word-spacing:0.02px;}
#t13_77{left:45px;bottom:186px;letter-spacing:0.13px;}
#t14_77{left:45px;bottom:170px;letter-spacing:0.11px;word-spacing:0.02px;}
#t15_77{left:45px;bottom:155px;letter-spacing:0.12px;}
#t16_77{left:45px;bottom:140px;letter-spacing:0.12px;}
#t17_77{left:45px;bottom:125px;letter-spacing:0.12px;}
#t18_77{left:45px;bottom:109px;letter-spacing:0.12px;}
#t19_77{left:432px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t1a_77{left:759px;bottom:786px;letter-spacing:-0.12px;}
#t1b_77{left:36px;bottom:748px;letter-spacing:-0.1px;}
#t1c_77{left:36px;bottom:729px;letter-spacing:-0.09px;word-spacing:-0.62px;}
#t1d_77{left:36px;bottom:711px;letter-spacing:-0.1px;}
#t1e_77{left:41px;bottom:693px;}
#t1f_77{left:58px;bottom:693px;letter-spacing:-0.09px;}
#t1g_77{left:58px;bottom:674px;letter-spacing:-0.09px;}
#t1h_77{left:63px;bottom:656px;}
#t1i_77{left:76px;bottom:656px;letter-spacing:-0.09px;}
#t1j_77{left:77px;bottom:638px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t1k_77{left:91px;bottom:619px;letter-spacing:-0.1px;}
#t1l_77{left:322px;bottom:627px;}
#t1m_77{left:77px;bottom:601px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t1n_77{left:91px;bottom:583px;letter-spacing:-0.09px;}
#t1o_77{left:91px;bottom:564px;letter-spacing:-0.09px;}
#t1p_77{left:41px;bottom:546px;}
#t1q_77{left:58px;bottom:546px;letter-spacing:-0.09px;}
#t1r_77{left:63px;bottom:528px;}
#t1s_77{left:76px;bottom:528px;letter-spacing:-0.09px;}
#t1t_77{left:547px;bottom:535px;}
#t1u_77{left:614px;bottom:748px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t1v_77{left:956px;bottom:755px;letter-spacing:-0.12px;}
#t1w_77{left:614px;bottom:729px;letter-spacing:-0.1px;}
#t1x_77{left:620px;bottom:711px;}
#t1y_77{left:636px;bottom:711px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t1z_77{left:620px;bottom:693px;}
#t20_77{left:636px;bottom:693px;letter-spacing:-0.09px;}
#t21_77{left:636px;bottom:674px;letter-spacing:-0.12px;word-spacing:0.02px;}
#t22_77{left:636px;bottom:656px;letter-spacing:-0.09px;}
#t23_77{left:620px;bottom:638px;}
#t24_77{left:636px;bottom:638px;letter-spacing:-0.09px;}
#t25_77{left:636px;bottom:619px;letter-spacing:-0.09px;}
#t26_77{left:797px;bottom:627px;}
#t27_77{left:36px;bottom:444px;letter-spacing:-0.09px;}
#t28_77{left:36px;bottom:425px;letter-spacing:-0.09px;}
#t29_77{left:36px;bottom:407px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t2a_77{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_77{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_77{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_77{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_77{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_77{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_77{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_77{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_77{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_77{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_77{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_77{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_77{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_77{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_77{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_77{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts77" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg77Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg77" style="-webkit-user-select: none;"><object width="1210" height="935" data="77/77.svg" type="image/svg+xml" id="pdf77" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_77" class="t s0_77">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_77" class="t s1_77">® </span>
<span id="t3_77" class="t s0_77">(NCCN </span>
<span id="t4_77" class="t s1_77">® </span>
<span id="t5_77" class="t s0_77">), All rights reserved. NCCN Guidelines </span>
<span id="t6_77" class="t s1_77">® </span>
<span id="t7_77" class="t s0_77">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_77" class="t s2_77">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_77" class="t s2_77">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_77" class="t s3_77">NCCN Guidelines Version 4.2024 </span>
<span id="tb_77" class="t s3_77">Occult Primary </span>
<span id="tc_77" class="t s4_77">NCCN Guidelines Index </span>
<span id="td_77" class="t s4_77">Table of Contents </span>
<span id="te_77" class="t s4_77">Discussion </span>
<span id="tf_77" class="t s5_77">OCC-A </span>
<span id="tg_77" class="t s5_77">1 OF 2 </span>
<span id="th_77" class="t s6_77">1 </span>
<span id="ti_77" class="t s7_77">For squamous cell carcinoma, adenocarcinoma, and poorly differentiated carcinoma. </span>
<span id="tj_77" class="t s6_77">2 </span>
<span id="tk_77" class="t s8_77">See Principles of Radiation Techniques (RAD-A) </span><span id="tl_77" class="t s7_77">and </span><span id="tm_77" class="t s8_77">Discussion</span><span id="tn_77" class="t s7_77">. </span>
<span id="to_77" class="t s6_77">3 </span>
<span id="tp_77" class="t s9_77">For doses &gt;70 Gy, some clinicians feel that the fractionation should be slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) to minimize toxicity. An </span>
<span id="tq_77" class="t s7_77">additional 2–3 doses can be added depending on clinical circumstances. </span>
<span id="tr_77" class="t s6_77">4 </span>
<span id="ts_77" class="t s7_77">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="tt_77" class="t s6_77">5 </span>
<span id="tu_77" class="t s8_77">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tv_77" class="t s7_77">. </span>
<span id="tw_77" class="t s6_77">6 </span>
<span id="tx_77" class="t s7_77">Based on published data, concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks </span>
<span id="ty_77" class="t s7_77">with single-agent cisplatin given every 3 weeks at 100 mg/m </span>
<span id="tz_77" class="t s0_77">2 </span>
<span id="t10_77" class="t s7_77">; 2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG 0129) </span>
<span id="t11_77" class="t s7_77">(Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35). When carboplatin and </span>
<span id="t12_77" class="t s7_77">5-FU are used, the recommended regimen is standard fractionation plus 3 cycles of chemotherapy [Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy </span>
<span id="t13_77" class="t s7_77">versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase </span>
<span id="t14_77" class="t s9_77">3 randomised trial. Lancet Oncol 2012;13:145-153]. Other fraction sizes (eg, 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or </span>
<span id="t15_77" class="t s7_77">altered fractionation with chemotherapy are efficacious, and there is no consensus on the optimal approach. In general, the use of concurrent systemic therapy/RT </span>
<span id="t16_77" class="t s7_77">carries a high toxicity burden; multiagent chemotherapy will likely further increase the toxicity burden. For any systemic therapy/RT approach, close attention should </span>
<span id="t17_77" class="t s7_77">be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration. Systemic therapy/RT should be performed by an experienced </span>
<span id="t18_77" class="t s7_77">team and should include substantial supportive care. </span>
<span id="t19_77" class="t s5_77">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t1a_77" class="t sa_77">1,2 </span>
<span id="t1b_77" class="t s5_77">DEFINITIVE: </span>
<span id="t1c_77" class="t s5_77">RT Alone </span>
<span id="t1d_77" class="t s5_77">• PTV </span>
<span id="t1e_77" class="t sb_77"></span><span id="t1f_77" class="t s5_77">High risk: Involved lymph nodes [this includes possible local </span>
<span id="t1g_77" class="t sc_77" data-mappings='[[14,"fi"]]'>subclinical inﬁltration at the high-risk level lymph node(s)] </span>
<span id="t1h_77" class="t sd_77">◊ </span><span id="t1i_77" class="t s5_77">Fractionation: </span>
<span id="t1j_77" class="t s5_77">– 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily </span>
<span id="t1k_77" class="t s5_77">Monday–Friday in 6–7 weeks </span>
<span id="t1l_77" class="t sa_77">3 </span>
<span id="t1m_77" class="t s5_77">– Mucosal dosing: 50–66 Gy (2.0 Gy/fraction) to putative </span>
<span id="t1n_77" class="t sc_77" data-mappings='[[28,"fi"]]'>mucosal sites, depending on ﬁeld size. Consider higher dose </span>
<span id="t1o_77" class="t s5_77">to 60–66 Gy to particularly suspicious areas </span>
<span id="t1p_77" class="t sb_77"></span><span id="t1q_77" class="t s5_77">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1r_77" class="t sd_77">◊ </span><span id="t1s_77" class="t s5_77">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1t_77" class="t sa_77">4 </span>
<span id="t1u_77" class="t s5_77">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t1v_77" class="t sa_77">5,6 </span>
<span id="t1w_77" class="t s5_77">• PTV </span>
<span id="t1x_77" class="t sb_77"></span><span id="t1y_77" class="t s5_77">High risk: Typically 70 Gy (2.0 Gy/fraction) </span>
<span id="t1z_77" class="t sb_77"></span><span id="t20_77" class="t s5_77">Mucosal dosing: 50–60 Gy (2.0 Gy/fraction) to putative mucosal </span>
<span id="t21_77" class="t sc_77" data-mappings='[[28,"fi"]]'>primary sites, depending on ﬁeld size and use of chemotherapy. </span>
<span id="t22_77" class="t s5_77">Consider higher dose to 60–66 Gy to particularly suspicious areas </span>
<span id="t23_77" class="t sb_77"></span><span id="t24_77" class="t s5_77">Low to intermediate risk: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy </span>
<span id="t25_77" class="t s5_77">(1.6–1.8 Gy/fraction) </span>
<span id="t26_77" class="t sa_77">4 </span>
<span id="t27_77" class="t s5_77">Either IMRT (preferred) or 3D-CRT is recommended when targeting the pharyngeal axis to minimize the dose to critical structures. Use of </span>
<span id="t28_77" class="t s5_77">proton therapy is an area of active investigation. Proton therapy may be considered when normal tissue constraints cannot be met by photon- </span>
<span id="t29_77" class="t s5_77">based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </span>
<span id="t2a_77" class="t se_77">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
